Carcinoma of Unknown Primary — Research

Carcinoma of Unknown Primary — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	2,027	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	791	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	154	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 76–100 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.